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VPAC1e proteins, translation of G protein-coupled receptors (GPCRs) mRNA takes place
at the endoplasmic reticulum (ER) where they are synthesized, folded and assembled. The molecular
mechanisms involved in the transport process of GPCRs from ER to the plasma membrane are poorly
investigated. Here we studied the mechanisms involved in glycosylation-dependent cell surface expression
and quality control of the receptor for Vasoactive Intestinal Polypeptide (VIP) VPAC1, a member of the B
family of GPCRs. Using biochemical and pharmacological techniques and ﬂuorescence microscopy, we have
shown that only a fraction of newly synthesized VPAC1 attains properly conformation that allows their cell
surface targeting. Misfolded or immature VPAC1 are taken in charge by co- and post-translational quality
control that involves: 1) calnexin-dependent folding strictly through a glycan-dependent mechanism, 2) BiP-
dependant folding, 3) translocation to the cytoplasm and proteasome-dependent degradation of improper
proteins, and 4) post-ER quality control check points. Our data suggest that VPAC1 expression/trafﬁcking
pathways are under the control of complex and precise molecular mechanisms to ensure that only proper
VPAC1 reaches the cell surface.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionG protein-coupled receptors (GPCRs), also referred to seven
transmembrane domain receptors, represent the largest family of
signal transducers for extracellular stimuli. Upon ligand binding,
GPCRs undergo conformational changes allowing the interaction of
cytoplasmic domains with heterotrimeric G proteins and thereafter
the activation of downstream effector pathways [1]. The magnitude
and the sensitivity of the responses are correlated with the G proteins
content of the cells and the level of receptors available at the cell
surface, a balance between intracellular trafﬁcking processes and
metabolism: synthesis, export, internalization and degradation [2].
Like for most transmembrane proteins, translation of GPCRs mRNA
takes place at the endoplasmic reticulum (ER) where they are
synthesized, folded and assembled [2,3]. Misfolded or disassembled
proteins will be translocated back to the cytosol where they are
degraded by the ubiquitin–proteasome system or aggregate and
accumulate in aggresomes (microtubule-dependant inclusion bodies)
[4,5]. Properly folded receptors are recruited and packaged in ER-
derived COPII-coated vesicles carrying the receptor to the ER-Golgi
intermediate complex (ERGIC). The receptor progresses through the, Université Libre de Bruxelles,
el.: +32 2 5554172; fax: +32 2
l rights reserved.Golgi-apparatus by mechanisms that are still a matter of debates [6]
then to the trans-Golgi network (TGN) where they are packaged in
TGN-derived vesicles to reach the cell surface. During their migration,
receptors undergo post-translational modiﬁcations (ie maturation of
glycosylation) to attain mature status [2,3]. Another vesicular way
delivering receptors at the cell surface is a consequence of receptor
internalization in response to agonist exposure and is subdivided in
three main steps: 1) Recruitment by activated receptor of the protein
machinery necessary for endocytosis. 2) Receptor internalization.
3) Vesicular trafﬁc that leads to cell surface re-expression of the
receptor or its degradation in intracellular compartments [7,8].
Although the events of the endocytic pathway are extensively studied,
molecular mechanisms involved in the transport process of GPCRs
from ER to the plasma membrane are rarely investigated.
Vasoactive Intestinal Polypeptide (VIP) is a neuropeptide that
contributes to regulation of intestinal motility and secretion, exocrine
and endocrine secretions and to homeostasis of the immune system
through interaction with two GPCRs named VPAC1 and VPAC2 [9]. A
previous study by Couvineau et al. showed that in VPAC1 asparagine
residues 58, 69 and 100 are in consensus sequences for N-glycosyla-
tion and indeed glycosylated. Mutation of Asn 58 and 69 causes
retention of receptors in intracellular compartments [10]. In the
present study, we studied the mechanisms involved in glycosylation-
dependent cell surface expression and quality control of VPAC1. First,
we evaluated the contribution of the ubiquitin–proteasome system by
inhibiting proteasome activity and bymutation into arginine of the six
Table 1
Characteristics of primary antibodies used in this study
Antibody Species Origin Use
Anti-BiP Rabbit polyclonal Stressgene © WB
Anti-calnexin Rabbit polyclonal Stressgene © WB
Anti-GAPDH Mouse monoclonal Chemicon © WB
Anti-MYC Mouse monoclonal Cell Signaling © WB, IP, IF
Anti-MYC Rabbit polyclonal Santa Cruz Biotechnology © IF
Anti-ubiquitin Mouse monoclonal Chemicon © WB
Anti-V5 Mouse monoclonal Invitrogen © IF
Anti-VPAC1 Rabbit polyclonal
(C-terminal epitope)
Gift from S. Schulz [13] WB
Anti-VPAC1 Mouse monoclonal
(N-terminal epitope)
Developed in the lab. [14] IP, IF
WB: western-blot, IP: immunoprecipitation, IF: immunoﬂuorescence.
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type and non-glycosylatable VPAC1 receptors expression. Second, we
evaluated putative and misrouted VPAC1 receptors interactions with
molecular chaperones known to be important in protein folding.
Finally, as previous studies showed that misrouted receptor mutants
can act as dominant-negative on cell surface expression of properly
folded receptors, we evaluated the effect of co-expression of wild-type
and non-glycosylatable VPAC1 receptors.
2. Materials and methods
2.1. Construction and expression of mutated and tagged VPAC1 receptors
The CHO cell line expressing wt VPAC1 has been detailed in a previous publication
[11]. The plasmid coding for non-glycosylated VPAC1 receptor (by mutation of the
glycosylatable Asn residues into Thr) and bearing a MYC-tag epitope at the C-terminus
was a kind gift from Dr. Alain Couvineau (France) [10]. Generation of mutated receptors
was achieved using the QuikChange Site-Directed Mutagenesis kit (Stratagene, LaJolla
CA, USA) according to the manufacturer's instructions as described [12]. For co-
expression experiments, a VPAC1 receptor bearing a V5-tag at the C-terminus was
constructed using pcDNA3.1/V5-His/TOPO expression kit according to the manufac-
turer's instructions (Invitrogen SA, Merelbeke, Belgium). Conﬁrmation of the expected
mutation and V5-tag insertion was achieved by DNA sequencing on an ABI automated
sequencing apparatus, using the BigDye Terminator Sequencing Prism Kit from ABI
(Perkin-Elmer, CA, USA). Following DNA ampliﬁcation using a midiprep endotoxin-free
kit (Promega, CA, USA), the complete nucleotide sequence of the receptor coding region
was veriﬁed by DNA sequencing. 20 μg of receptors coding region was transfected by
electroporation in CHO cell line expressing aequorin (kindly provided by Vincent
Dupriez, Euroscreen SA, Belgium). For the cell line co-expressing non-glycosylatable
and wt receptors, 15 μg of both receptors coding region was used for transfection.
Selection was carried out in culture medium [50% HamF12; 50% DMEM; 10% fetal calf
serum; 1% penicillin (10 mU/ml); 1% streptomycin (10 μg/ml); 1% l-glutamine
(200 mM), PAA, Pashing, Austria], supplemented with 600 μg geneticin (G418)/ml
culture medium. After 10 to 15 days of selection, isolated colonies were transferred to
24 well plates and grown until conﬂuence. Selection of cell clones expressing receptors
was performed by dot-blot analysis. Brieﬂy, 10 μg of protein lysate was directly spotted
on nitrocellulose membrane and receptors were detected using monoclonal antibodies
against MYC-tag, V5-tag or polyclonal antibody against C-terminal domain of VPAC1
receptors (see below), a gift from Dr Stephan Schulz (Germany) [13].
2.2. Immunoprecipitation and western-blot
Cells were lysed following 60 min incubation on ice in buffer consisting in 50 mM
Hepes, 150 mM NaCl, 10 mM EDTA, 10 mM Na4P2O7, 100 mM NaF, 2 mM orthovanadate,
0,5% n-dodecyl-β-D-maltoside (or 1.5% CHAPS for co-immunoprecipitation experi-
ments) and protease inhibitors cocktail (Complete®, Roche Applied Science, Vilvoorde,
Belgium) pH 7.5. The remaining insoluble material was eliminated by centrifugation at
15,000 g for 5 min at 4 °C. Protein concentration was evaluated by using BCA assay kit
(Pierce, Rockford IL, USA). For immunoprecipitation experiments, the same amount of
protein was added to 50 μl of a 10% protein G sepharose suspension (GE Healthcare,
Diegem, Belgium) coated during 1 h at room temperature with 2 μg of monoclonal anti-
VPAC1 antibody developed in the laboratory by genetic immunization and raised
against the N-terminus of VPAC1 (see [14] for details) or 0.2 μl of monoclonal anti-MYC
antibody (Cell Signaling, Danvers MA, USA). After 150 min incubation under rotating
agitation at 4 °C, the sepharose beads were separated by centrifugation and washed
three times with buffer consisting in Hepes 30 mM, NaCl 30 mM and Triton X100 0.1%.
The ﬁnal beads pellet was resuspended in SDS sample buffer consisting of 125 mM Tris,
10% β-mercaptoethanol, 4% SDS, 20% glycerol, and 0.02% bromophenol blue, pH 6.8.
After heating at 60 °C for 10 min, the samples were resolved by SDS-PAGE using a 7.5–
10% gel and transferred on a nitrocellulose membrane. For western-blot, 60 μg of
protein lysate was directly resolved by SDS-PAGE. Nitrocellulose membrane was
incubated in blocking buffer (PBS with 5% milk [or 3% BSA for ubiquitin detection] and
0.1% tween 20) for 1 h at room temperature then probed with polyclonal anti-VPAC1
(1:2000) [13], monoclonal anti-MYC (1:20,000, Cell Signaling, Danvers MA, USA),
monoclonal anti-ubiquitin (1:20,000, mAb1510, Chemicon, Temecula CA, USA),
polyclonal anti-calnexin (1:2500, Stressgene, Ann Arbor MI, USA), polyclonal anti-BiP
(1:2500, Stressgene, Ann Arbor MI, USA) or monoclonal anti-GAPDH (1:30,000,
Chemicon, Temecula CA, USA) antibodies diluted in PBS+1% milk (or 3% BSA for
ubiquitin detection)+0.1% tween 20 overnight at 4 °C. Membranes were washed three
times in PBS+0.1% tween 20, then probed with HRP goat anti-rabbit or anti-mouse
antibodies (Pierce, Rockford IL, USA)diluted1:50,000 inPBS+0.1% tween20 for 1h at room
temperature. Proteins were visualized using SuperSignal® West Pico Chemiluminescent
Substrate (Pierce, Rockford IL, USA). Primary antibodies used are described in Table 1.
2.3. Deglycosylation of the immunoprecipitated VPAC1
The immunoprecipitated receptors were deglycosylated after elution from anti-
VPAC1 coated protein G beads with 50 mM sodium phosphate, 0.5% SDS and 40 mM
DTT pH 7.5. Before enzyme reaction, samples were diluted 10 fold with 50 mM sodiumphosphate pH 7.5 supplemented with 1% NP-40 for PNGaseF digestion or with 50 mM
sodium phosphate pH 5.5 for EndoH digestion. 25 mU of PNGaseF (New England
BioLabs, Ipswich MA,USA) or 100 mU of EndoH (New England BioLabs, Ipswich MA,
USA) was added to samples and after 1 hour incubation at 37 °C the reaction was
stopped by adding SDS sample buffer.
2.4. Immunoﬂuorescence
Cells were cultured on 18 mm glass slides, washed in phosphate buffer saline (PBS)
and ﬁxed with −20 °C absolute methanol for 10 min. Unspeciﬁc protein binding was
prevented by 30 min incubation with 5% foetal bovine serum. The cells were then
incubated overnight at 4 °C with monoclonal anti-VPAC1 antibody (2 μg/ml),
monoclonal anti-MYC antibody (1:3000, Cell Signaling, Danvers MA, USA), monoclonal
anti-V5 antibody (1:1000, Invitrogen SA, Merelbeke, Belgium) or a mixture of
monoclonal anti-V5 antibody (1:1000) and polyclonal anti-MYC antibody (1:100,
Santa Cruz Biotechnology, Santa Cruz CA, USA). The primary antibodies were diluted in
PBS – 1% foetal bovine serum – 0.1% sodium azide. After three washes and a second
30 min incubation at room temperature with foetal bovine serum, the cells were
incubated for 30 min at room temperature with FITC-conjugated-γ-chain-speciﬁc goat
anti-mouse IgG (Sigma Chemicals, MO, USA) (1:150), texas red-conjugated donkey anti-
rabbit IgG (Jacksons Immunologicals, CA, USA) (1:150) or a mixture of both secondary
antibodies diluted in the same solution as the primary antibody. Omission of the
primary or secondary antibody resulted in the absence of labelling. After 3 rinses in PBS,
coverslips were mounted with Vectashield mounting medium (Vector, Burlingame CA,
USA) before viewing under a ﬂuorescent Zeiss axiovert microscope. Images were
acquired using an axiocam MRb camera (Zeiss).
2.5. Membrane preparation
Membranes were prepared from scraped cells lysed in 1mMNaHCO3 by immediate
freezing in liquid nitrogen. After thawing, the lysate was ﬁrst centrifuged at 4 °C for
10 min at 400 g and the supernatant was further centrifuged at 20,000 g for 10 min. The
resulting pellet, resuspended in 1 mM NaHCO3 was used immediately as a crude
membrane fraction.
2.6. Adenylate cyclase activation assay
Adenylate cyclase activity was determined by the procedure of Salomon et al., as
described [15]. Membrane proteins (3–15 μg) were incubated in a total volume of 60 μl
containing 0.5 mM [α32P]-ATP, 10 μM GTP, 5 mM MgCl2, 0.5 mM EGTA, 1 mM cAMP,
1 mM theophylline, 10 mM phospho(enol)pyruvate, 30 μg/ml pyruvate kinase and
30 mM Tris–HCl at a ﬁnal pH of 7.8. The reaction was initiated by membranes addition
and was terminated after 15 min incubation at 37 °C by adding 0.5 ml of a 0.5% sodium
dodecyl-sulfate solution containing 0.5 mM ATP, 0.5 mM cAMP and 20,000 cpm [3H]-
cAMP. cAMP was separated from ATP by two successive chromatographies on Dowex
50 W×8 and neutral alumina.
2.7. Binding studies
Binding studies were performed by using as tracer [125I]-VIP. The non-speciﬁc
binding was deﬁned as the residual binding in the presence of 1 μM unlabelled VIP.
Binding was performed for 30min at 23 °C in a total volume of 120 μl containing 20 mM
Tris-maleate, 2 mM MgCl2, 0.1 mg/ml bacitracin, 1% bovine serum albumin (pH 7.4)
buffer. Three to 30 μg of protein was used per assay. Bound and free radioactivity were
separated by ﬁltration through glass-ﬁbre GF/C ﬁlters pre-soaked for 24 h in 0.01%
polyethyleneimine and rinsed three times with a 20 mM (pH 7.4) ice cold sodium
phosphate buffer containing 0.8% bovine serum albumin.
2.8. Receptor internalization and trafﬁcking
Receptor internalizationwas deﬁned as the percentage of cell surface receptors that
were no longer accessible to the monoclonal anti-VPAC1 antibody, after agonist
exposure. Cells expressing VPAC1 or mutated receptor were incubated with agonist at
Fig. 2. Effect of lactacystin treatment on expression of wt and ng-VPAC1. CHO cells
expressing wt (A, C) or ng-VPAC1 (B, D) were treated (lane 3) or not (lane 2) for 6 h with
5 μM lactacystin, lysed and submitted to immunoprecipitation with monoclonal anti-
VPAC1 (A, C) or monoclonal anti-MYC (B, D). The immunoprecipitates were resolved on
9% acrylamide-SDS gels, transferred to nitrocellulose membrane and blotted with
polyclonal anti-VPAC1 (A) or monoclonal anti-MYC (B). The membranes were then
stripped and re-probed using monoclonal anti-ubiquitin (C, D). Untransfected CHO cells
were submitted to immunoprecipitation with monoclonal anti-VPAC1 (A, C) or
monoclonal anti-MYC (B, D) as negative control (lane 1). The arrows indicate IgG
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a 5 mM EDTA/EGTA PBS solution, harvested by centrifugation (500 g, 4 °C, 4 min),
washed once with PBS solution and resuspended at density of 3.105 cells/assay in 100 μl
PBS-BSA 0.1%, containing 0.1 μg monoclonal anti-VPAC1 antibody. After 30 min
incubation at 4 °C, the cells were washed with PBS-BSA 0.1% and then incubated with
FITC-conjugated-γ-chain-speciﬁc goat anti-mouse IgG (Sigma Chemicals, MO, USA) for
30 min on ice in the dark. The labelled cells were washed and resuspended in 250 μl
PBS-BSA 0.1%. The ﬂuorescence level was analyzed using a FACScalibur (Becton
Dickinson) and the data were processed using the cell quest software (Becton
Dickinson). Basal ﬂuorescence was determined from sample of untransfected CHO
cells. Propidium iodide (10 μg/ml) was used to exclude debris and dead cells from our
analysis.
2.9. Peptide synthesis
The peptides used were synthesized in our laboratory as described [16,17]. Peptide
purity was assessed by capillary electrophoresis, and conformity by electrospray MS.
2.10. Data analysis
All competition curves, dose-response curves, IC50 and EC50 values were
calculated using non-linear regression (GraphPad Prism software). Statistical analyses
(Mann Whitney test) were performed with the same software.
3. Results
3.1. Study of the molecular forms of VPAC1
The misrouted non-glycosylatable VPAC1 receptor (ng-VPAC1),
generated by mutation of asparagines located in N-terminus and
included in consensus sequences for N-glycosylation and labelled
with a MYC epitope, [10] was ﬁrst stably expressed in CHO cells. We
performed immunoprecipitation experiments, using a monoclonal
anti-VPAC1 antibody, followed by western-blot using a polyclonal
anti-VPAC1 antibody to study the molecular forms of VPAC1 and ng-
VPAC1. In cells expressing VPAC1, anti-VPAC1 recognized two broad
bands with an apparent molecular weight of 70 and 140 kDa. The
proﬁle was unchanged after digestion with EndoH, a glycosidase that
cleaves only high-mannose oligosaccharides present on immature
glycoprotein of the ER. Treatment with PNGase F, that cleaves all forms
of N-glycosylation, generated two sharper bands with apparent
molecular weight of 45 and 100 kDa (Fig. 1A). In all conditions, anti-
VPAC1 also recognized an additional band migrating at the top of theFig. 1.Molecular forms of VPAC1. (A) VPAC1 and (B) non-glycosylatable VPAC1 (ng-VPAC1)
receptors were immunoprecipitated using monoclonal anti-VPAC1 from lysate of stably
transfected CHO cells. Immunoprecipitated VPAC1 was further incubated for 1 h at 37 °C
with 100 mU EndoH (A lane 3) or 25 mU of PNGaseF (A lane 4). The immunoprecipitates,
digested or not by glycosidases, were then resolved on 10% acrylamide-SDS gels,
transferred to nitrocellulose membrane and blotted with polyclonal anti-VPAC1. In each
experiment, untransfected CHO cells were submitted to immunoprecipitation with
monoclonal anti-VPAC1 as negative control (lane 1). The arrows indicate IgG eluted from
protein A/sepharose beads after immunoprecipitation. Representative of three
experiments.
eluted from protein A/sepharose beads after immunoprecipitation. Representative of
three experiments.gel and whom molecular weight cannot be reliably extrapolated. For
ng-VPAC1 expressing cells, anti-VPAC1 detected two sharp bands with
apparent molecular weight of 45 and 100 kDa (Fig. 1B). During those
assays, several observations indicated that monoclonal anti-VPAC1
antibody recognized poorly non-glycosylated VPAC1 as the intensity
of the signal was much weaker than that expected from receptor
quantiﬁcation with other antibodies (data not shown). We therefore
used anti-MYC antibody to detect ng-VPAC1 for the rest of the study.
3.2. Involvement of the ubiquitin–proteasome system in the quality
control of the expression of VPAC1
Protein translation is regulated by ER-associated quality control
machinery that detects misfolded and/or misassembled proteins and
induces their translocation in the cytoplasm for degradation by the
ubiquitin–proteasome system [18]. We evaluated the effect of
lactacystin (a speciﬁc proteasome inhibitor) on expression of wt
VPAC1 and misrouted ng-VPAC1. Treatment of the cells for 6 h with
5 μM lactacystin increased the expression level of all molecular forms
of wt and ng-VPAC1 evaluated by immunoprecipitation followed by
western-blot (Fig. 2A–B). However, the effect was stronger in ng-
VPAC1 expressing cells and an additional band with an apparent
molecular weight of 100 kDa was detected in cells expressing wt
receptors. As inhibition of the proteasome could induce accumulation
Fig. 3. Effect of mutation of intracellular lysines on expression of wt and ng-VPAC1.
A) CHO cells expressing wt (lanes 2–3) or nubi-VPAC1 (lanes 4–5), inwhich intracellular
lysines were mutated into arginine to prevent ubiquitination, were treated (lanes 3, 5)
or not (lane 2, 4) for 6 h with 5 μM lactacystin, lysed and submitted to immuno-
precipitationwith monoclonal anti-VPAC1. B) CHO cells expressing ng-VPAC1 (lanes 2–3)
or nubi/ng-VPAC1 (lanes 4–5), inwhich intracellular lysines weremutated into arginine to
prevent ubiquitination, were treated (lanes 3, 5) or not (lane 2, 4) for 6 h with 5 μM
lactacystin, lysed and submitted to immunoprecipitation with monoclonal anti-MYC.
The immunoprecipitates were resolved on 9% acrylamide-SDS gels, transferred to
nitrocellulose membrane and blotted with polyclonal anti-VPAC1 (A) or monoclonal
anti-MYC (B). Untransfected CHO cells were submitted to immunoprecipitation with
monoclonal anti-VPAC1 (A) or monoclonal anti-MYC (B) as negative control (lane 1). The
arrows indicate IgG eluted from protein A/sepharose beads after immunoprecipitation.
Representative of three experiments.
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tion experiments and probed the nitrocellulose membrane with an
anti-ubiquitin antibody. We were however unable to detect any
speciﬁc band even after increasing lactacystin incubation times up to
24 h or adding N-ethylmaleimide in protein lysates (Fig. 2C–D). We
used as positive control of the experimental protocol the detection of
ubiquitinated Tau in brain extracts from Alzheimer's patient (data not
shown).
To directly investigate potential involvement of the ubiquitin–
proteasome system in VPAC1 translation and maturation, we replaced
all six lysine residues located in intracellular domain by arginine to
prevent receptor ubiquitination in wt (nubi-VPAC1) and ng-VPAC1
(nubi/ng-VPAC1). The 10 CHO cell clones obtained after transfection
displayed a signiﬁcantly higher receptor density than those expressing
the wt and ng-VPAC1. VIP potency and efﬁcacy to stimulate adenylate
cyclase activation were increased in cells expressing nubi-VPAC1, a
result that could be explained by higher expression level and the
presence of spare receptors that shifted the dose-effect curves to
lower concentrations (Table 2). We were unable to detect any
biological activity or VIP speciﬁc binding for membrane prepared
from cells expressing nubi/ng-VPAC1. VPAC1 is rapidly internalized
following agonist exposure but does not recycle back to the cell
surface after agonist removal within 2 h [14]. In addition to
phosphorylation and arrestin recruitment and binding, targeting of
agonist stimulated receptor to the endocytic pathway can be achieved
by ubiquitination of the receptor at the cell surface [4]. This is probably
not the case as wt and nubi-VPAC1 displayed the same internalization
and recycling proﬁle by FACS analysis (Table 2).
We next evaluated by immunoprecipitation followed by western-
blot the effect of lactacystin treatment. As shown in Fig. 3, expression
levels of nubi-VPAC1 and nubi/ng-VPAC1 were almost unaffected by
lactacystin treatment. As observed for cells expressing wt VPAC1 and
treated with lactacystin, anti-VPAC1 antibody recognized a band with
an apparent molecular weight of 100 kDa in nubi-VPAC1 for both
treated and untreated cells.
Finally, we studied cellular localization of the receptors using
immunoﬂuorescence in cells treated or not for 6 h with 5 μM
lactacystin. As shown in Fig. 4, wt VPAC1weremainly expressed at the
cell surface with some cells exhibiting a slight granular intracellular
labelling. Lactacystin treatment slightly increased receptor labelling at
the cell surface and in intracellular compartment. Receptor labelling of
cells expressing nubi-VPAC1 was similar to that of wt receptor with an
increase in intracellular labelling but was not modiﬁed by lactacystin
treatment. As described previously, the ng-VPAC1 remained trapped
into the cells in a perinuclear compartment and we found that
lactacystin treatment increased labelling intensity. The nubi/ng-
VPAC1 was not clearly identiﬁed at the cell surface but labelling was
more diffuse in intracellular compartments and not limited to a dense
perinuclear area and was not modiﬁed by lactacystin treatment.Table 2
Pharmacological properties of wt and mutated VPAC1
VPAC1 nubi-VPAC1
Binding studies
VIP IC50 (nM) 1.1±0.2 1.3±0.2
Receptor density (pmol/mg prot) 10.8±0.4 24.4±0.6⁎⁎
Adenylate cyclase
VIP EC50 (nM) 1.5±0.3 0.32±0.02⁎⁎
Basal (pmol/min mg prot) 58±8 79±6⁎
VIP Emax (pmol/min mg prot) 201±10 277±15⁎
Internalization and recovery (% receptors at cell surface)
30 min VIP 1 μM treatment 20±3% 24±3%
30 min recovery 18±3% 20±4%
60 min recovery 17±2% 22±2%
120 min recovery 22±3% 26±3%
⁎pb0.05 and ⁎⁎pb0.01 evaluated by Mann Whitney test.All together, these results suggest that the quality control processes
that regulate the expression of VPAC1 target ng-VPAC1 and a fraction of
wt VPAC1 receptors to the proteasome for degradation.
3.3. Interaction of VPAC1 with quality control chaperones
Calnexin is an ER resident chaperone that usually binds N-linked
glycans of proteins through its lectin binding-domain and helps
nascent and newly synthesized proteins to acquire proper conforma-
tion. However, recent data have also suggested that binding of calnexin
can occur via glycosylation-independent mechanisms [19]. To inves-
tigate the potential involvement of calnexin in VPAC1 folding, we
performed co-immunoprecipitation andwestern-blot experiments. As
shown in Fig. 5, immunoprecipitation of the receptors followed by
membrane probingwith anti-calnexin antibody revealed that calnexin
(apparent as a 95 kDa band) co-immunoprecipitated only with the
glycosylated receptors: wt VPAC1 and nubi-VPAC1 (Fig. 5B–C).
Stripping of the membrane and reprobing with anti-receptor anti-
bodies conﬁrmed that cell lysates did express receptors (Fig. 5D–E).
Western-blot analysis using anti-calnexin and anti-GAPDH antibodies
indicated that all samples expressed similar levels of calnexin (Fig. 5A).
The same approach was used to study interaction between VPAC1 and
BiP, another ER resident chaperonewhombinding to nascent protein is
independent of the glycosylation status. As shown in Fig. 6, we found
that BiP (apparent as an 80 kDa band) co-precipitated with wt, nubi-
VPAC1, ng-VPAC1 and nubi/ng-VPAC1 (Fig. 6B–E). Western-blot
analysis using anti-BiP and anti-GAPDH antibodies indicated that all
samples expressed similar levels of BiP (Fig. 6A).
3.4. Effect of co-expression of wt and misrouted VPAC1 receptors
Previous studies showed that co-expression of misrouted receptor
mutants and properly folded receptors can inﬂuence their cellular
localization [20]. To evaluate if such a mechanism occurs with VPAC1,
we stably co-expressed in CHO cells both wt and ng-VPAC1 receptors.
In order to discriminate the two receptors, as our anti-VPAC1
antibodies recognized epitopes localized in both receptors, we
constructed a VPAC1 receptor bearing a V5-tag at the C-terminus. As
Fig. 4. Cellular localization of wt and mutated VPAC1. CHO cells stably transfected with wt VPAC1, nubi-VPAC1, ng-VPAC1 or nubi/ng-VPAC1 were treated (bottom panels) or not (top
panels) for 6 h with 5 μM lactacystin and then labelled using monoclonal anti-VPAC1 (wt and nubi-VPAC1) or monoclonal anti-MYC (ng- and nubi/ng-VPAC1). Receptors were
visualized using FITC-conjugated goat anti-mouse IgG using axiovert microscope equipped with apotome. Scale bar is 10 μM and represents scale for all panels.
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veriﬁcation that insertion of the V5-tag did not modify VIP afﬁnity nor
activity, as well as receptor internalization and trafﬁcking proﬁles
(Table 3), we studied properties of CHO cells co-expressing VPAC1-V5
and ng-VPAC1. Immunoﬂuorescence studies conﬁrmed that both
receptors were indeed expressed in the same cells. Like wt VPAC1,
VPAC1-V5 was mainly expressed at the cell surface while ng-VPAC1
remained trapped in a perinuclear compartment when expressed
alone in CHO cells (Fig. 7). In cells co-expressing the two receptors,
VPAC1-V5 was still expressed at the cell surface but intracellular
labelling was increased and ng-VPAC1 labelling appeared more
broadly distributed in intracellular compartment but was never
detected at the cell surface (Fig. 7).
3.5. Rescue of misrouted ng-VPAC1 by lowering culture temperature
Even in the presence of lactacystin thatmarkedly increased receptor
expression, the pharmacological properties of ng-VPAC1 cannot be
studied. Based on our previous study showing that lowering culture
temperature allowed the expression of a misrouted VPAC2 mutant
at the cell membrane [21], we cultured CHO cells expressing ng-VPAC1
at 30 °C for 72 h. In parallel, we also studied the properties of
VPAC1 receptors expressed in cells treated with tunicamycin, an
inhibitor of N-glycosylation. As shown in Fig. 8, we were able to detect
125[I]-binding on membrane prepared from CHO cells expressing wt
VPAC1 (treated or not for 24 h with 2 μg/ml tunicamycin) or ng-VPAC1.
VIP IC50 values were similar for all preparations (wt VPAC1 [IC50=1.1±
0.2 nM], wt VPAC1+tunicamycin [IC50=1.6±0.3 nM], ng-VPAC1
[IC50=2.5±0.5 nM]) but we found that tunicamycin reduced expression
levels of VPAC1 (3.2±0.2 pmol/mg protein), similarly ng-VPAC1 receptor
density was smaller (2.2±0.2 pmol/mg protein). VIP potency was also
comparable (wt VPAC1 [EC50=1.5±0.3 nM], wt VPAC1+tunicamycin
[EC50=1.5±0.4 nM], ng-VPAC1 [EC50=3.6±0.5 nM]) but VIP induced
maximal cAMP production was reduced following tunicamycin treat-
ment (Emax=137±9) and for ng-VPAC1 (Emax=102±8) as compared towt
VPAC1 (Emax=201±10) (Fig. 8). We observed that lowering culture
temperature of CHO cells expressing ng-VPAC1 to 30 °C increased
receptor expression levels evaluated by both microscopy and western-
blot (Fig. 9). Immunoﬂuorescence studies also showed that ng-VPAC1labelling wasmore widely distributed in cells cultured at 30 °C (Fig. 9A)
and if the receptors remain mainly localized in intracellular compart-
ments it is reasonable to propose that a small fraction reaches the cell
surface. As expected, immunoﬂuorescence studies indicated that
tunicamycin treatment signiﬁcantly reduces cell surface labelling of
VPAC1 but induces pronounced granular intracellular labelling
(Fig. 10A). Similarly, tunicamycin treatment led to the almost complete
disappearance of the 70 kDa mature VPAC1 and induced accumulation
of the 45 kDa precursor form (Fig. 10B).
4. Discussion
Although the magnitude and the sensitivity of the responses
elicited by GPCRs are correlated with the level of receptors available at
the cellular membrane, little is known about the speciﬁc co- and post-
translational mechanisms associated with the regulation of their cell
surface expression. Here, we used the human VPAC1 receptor and a
non-glycosylatable mutant (ng-VPAC1) that remains trapped in the ER
expressed in CHO cells as models to investigate these mechanisms.
The results show that VPAC1 is synthesized as a mature
N-glycosylated 70 kDa receptor. The non-glycosylated and degly-
cosylated receptors were detected as a 45 kDa protein. Immuno-
precipitation experiments also indicate that VPAC1 can exist as a
140 kDa protein. In line with recent ﬁndings of Harikumar et al.,
demonstrating that VPAC1 can form homodimers [22], this result
suggests that the 140 kDa band observed could correspond to
mature VPAC1 homodimers. This is further supported by the
observation that the 70 and 140 kDa forms of the receptors
are preserved after EndoH but not PNGase F treatment. Similarly,
ng-VPAC1 may exist as a 100 kDa protein, a molecular form also
observed following PNGase F treatment of immunoprecipitated
VPAC1, that could correspond to homodimers of non-glycosylated
VPAC1 and suggesting that dimerization of VPAC1 could be an
early event taking place in the ER. This result is in agreement with
the observation that VPAC1 and VPAC2 make heterodimers with
secretin receptors that remain trapped into the cells [22]. Other
studies, using ﬂuorescence or luminescence resonance energy
transfer (FRET and BRET), also revealed that several GPCR
dimerize in the endoplasmic reticulum [23,24]. However, we
Fig. 5. Interaction between VPAC1 and calnexin. A) Total cell lysate of untransfected CHO cells (lane 1) or cells stably transfected with wt (lane 2), nubi-VPAC1 (lane 3), ng-VPAC1
(lane 4) or nubi/ng-VPAC1 (lane 5) were resolved on 7.5% acrylamide-SDS gels, transferred to nitrocellulose membrane and blotted with polyclonal anti-calnexin (upper panel). The
membranewas then stripped and re-probed using monoclonal anti-GAPDH (bottom panel). The same samples were submitted to immunoprecipitationwith monoclonal anti-VPAC1
(middle panels) or monoclonal anti-MYC (right panels). The immunoprecipitates were resolved on 7.5% acrylamide-SDS gels, transferred to nitrocellulose membrane and blotted
with polyclonal anti-calnexin (B–C). The membranes were then stripped and re-probed using polyclonal anti-VPAC1 (D) or monoclonal anti-MYC (E). Untransfected CHO
cells were submitted to immunoprecipitation with monoclonal anti-VPAC1 (B, D) or monoclonal anti-MYC (C, E) as negative control (lane 1). The arrows indicate IgG eluted from
protein A/sepharose beads after immunoprecipitation. Representative of three experiments.
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correspond to solubilisation artefact rather than functional
dimers. Indeed, they are visualized after denaturating electro-
phoresis and mainly detected following receptor immunopreci-
pitation but not direct western-blot. Similarly, for cell lines
expressing high receptor density, we also observed bands with
apparent molecular weight greater than 150 kDa.
Several converging evidences also suggest that synthesis of VPAC1
receptors is regulated by ER-associated quality control machinery that
induces their translocation in the cytoplasm for degradation by the
ubiquitin–proteasome system. Indeed, treatment of cells expressing
wt VPAC1 or ng-VPAC1 by lactacystin, a speciﬁc proteasome inhibitor,
increases receptor expression levels as shown by immunoprecipita-
tion experiments and microscopy. Similarly, the cell clones selected
after transfection with mutated receptors, in which all six lysine
residues located in intracellular domain were replaced by arginine to
prevent receptor ubiquitination, all displayed a signiﬁcantly higher
receptor density as compared to wt VPAC1 and ng-VPAC1 expressing
cells, respectively. In addition, these non-ubiquitinatable receptors
were insensitive to lactacystin treatment. However, proteasome
inhibition, following lactacystin treatment or mutation of intracellular
lysines, did not allow cell surface targeting of ng-VPAC1, suggestingthat additional quality controls occur behind the ER as seen for rho-
dopsin but also GnRHR, olfactory, chemokines and α-adrenergic
receptors [3]. Interestingly, the 100 kDa molecular form of VPAC1,
which corresponds to potential homodimers of non-glycosylated
receptor, was detected after immunoprecipitation of non-ubiquitina-
table VPAC1 or wt VPAC1 solubilised from cells treated with
lactacystin. We also observed by using microscopy that intracellular
labelling of VPAC1 was slightly increased following lactacystin
treatment of the cells or mutation of intracellular lysines. We were
however unable to detect ubiquitinated receptors after immunopre-
cipitation followed by protein labelling with anti-ubiquitin antibody.
This could be explained by the fact that ubiquitinated receptors are no
more recognized by anti-receptor antibodies or that the amount of
ubiquitinated receptors, even after lactacystin treatment, is too low to
be detected. Indeed, most of the studies describing ubiquitinated
proteins used exogenously over-expressed ubiquitin, further support-
ing the idea that expression levels could be critical. Nevertheless, all
together these results suggest that a fraction of wt VPAC1 fails to adopt
a mature/properly folded and stable conformation and is degraded by
ER-associated quality control. Quality control system ensures that only
mature and stable proteins are produced by the secretory pathway,
and is adapted to handle any conditions that result in a protein
Fig. 6. Interaction between VPAC1 and BiP. A) Total cell lysate of untransfected CHO cells (lane 1) or cells stably transfected with wt (lane 2), nubi-VPAC1 (lane 3), ng-VPAC1 (lane 4) or
nubi/ng-VPAC1 (lane 5) were resolved on 7.5% acrylamide-SDS gels, transferred to nitrocellulose membrane and blotted with polyclonal anti-BiP (upper panel). The membrane was
then stripped and re-probed usingmonoclonal anti-GAPDH (bottom panel). The same samples were submitted to immunoprecipitationwithmonoclonal anti-VPAC1 (middle panels)
or monoclonal anti-MYC (right panels). The immunoprecipitates were resolved on 7.5% acrylamide-SDS gels, transferred to nitrocellulosemembrane and blottedwith polyclonal anti-
BiP (B–C). The membranes were then stripped and re-probed using polyclonal anti-VPAC1 (D) or monoclonal anti-MYC (E). Untransfected CHO cells were submitted to
immunoprecipitation with monoclonal anti-VPAC1 (B, D) or monoclonal anti-MYC (C, E) as negative control (lane 1). The arrows indicate IgG eluted from protein A/sepharose beads
after immunoprecipitation. Representative of three experiments.
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defective proteins that potentially interfere with normal cell function
[19]. Proteins can fail quality control because of multiple factors such
as the lack of post-translational modiﬁcation (as shown here forTable 3
Pharmacological properties of wt and V5-tagged VPAC1
VPAC1 VPAC1-V5
Binding studies
VIP IC50 (nM) 1.1±0.2 1.2±0.3
Receptor density (pmol/mg prot) 10.8±0.4 12.2±0.8
Adenylate cyclase
VIP EC50 (nM) 1.5±0.3 0.9±0.2
Basal (pmol/min mg prot) 58±8 53±4
VIP Emax (pmol/min mg prot) 201±10 225±13
Internalization and recovery (% receptors at cell surface)
30 min VIP 1 μM treatment 20±3% 23±3%
30 min recovery 18±3% 17±4%
60 min recovery 17±2% 26±2%
120 min recovery 22±3% 25±3%VPAC1 but also other receptors like AT1R and FSHR), mutation and
truncation that interfere with protein folding (as seen for vasopressin
receptors and rhodopsin), orphan subunit of oligomeric complexes, or
oligomers that fail to reach their quaternary structure [3]. The
observation that wt receptors are regulated by quality control is not
unique to VPAC1 since the same phenomenonwas observed for GnRH,
LH and δ-opioid receptors [20,25,26]. Actually, several authors have
suggested that a large amount of some newly synthesized proteins are
degraded by the proteasome and hypothesized that this proteolytic
pathway is a general mechanism used to regulate protein expression
[19].
Misfolded and unassembled proteins retained in the ER frequently
display prolonged interaction with molecular chaperones that in
addition to assist the folding of newly synthesized proteins also act as
sensors of the quality control machinery and target misfolded proteins
for degradation [18]. Calnexin is a lectin-binding chaperone, located at
the membrane of ER near the translocon, interacting with nascent
glycoproteins and preferentially with monoglucosylated oligosacchar-
ides. Because some non-glycosylated proteins binds to calnexin and
mutations in the calnexin lectin site do not disturb this interaction, a
glycan-independent polypeptide binding has also been proposed [19].
Fig. 7. Visualization by double colour immuoﬂuorescence of V5-tagged and ng-VPAC1. CHO cells stably transfected with V5-tagged VPAC1 (top panels), ng-VPAC1 (middle panels) or
both (bottom panels) were labelled using a mixture of mouse monoclonal anti-V5 and rabbit polyclonal anti-MYC. Receptors were visualized using FITC-conjugated goat anti-mouse
IgG (green) and texas red-conjugated donkey anti-rabbit IgG (red) using axiovert microscope equipped with apotome. Scale bar is 10 μM and represents scale for all panels.
1670 I. Langer et al. / Biochimica et Biophysica Acta 1783 (2008) 1663–1672Here we show that calnexin is involved in VPAC1 folding and that
VPAC1 interacts with calnexin exclusively through glycan-dependent
mechanism as mutation of asparagines located in N-terminus and
included in consensus sequences for N-glycosylation completely
abolished this interaction. VPAC1 is also able to interact with BiP
(Grp78), the most abundant ER chaperone that binds to nascent chain
and recognizes preferentially the peptides enriched in hydrophobic
amino acids [19]. Molinari and Helenius observed that directFig. 8. Pharmacological properties of wt and non-glycosylated VPAC1. Left panel:
Inhibition of [125I]-VIP binding to membranes from CHO cells expressing wt VPAC1 and
treated or not for 24 h with 2 μg/ml tunicamycin or ng-VPAC1 and grown for 72 h at
30 °C by increasing concentrations of VIP. Right panel: Adenylate cyclase stimulation by
VIP of the samemembranes used in the left panel. Means of three experiments, the IC50
and EC50 values are given in the text.interaction with calnexin occurs if glycans are located within 50
residues from the protein N-terminus. Glycoproteins that have their
glycans located in distal sequences associate ﬁrst with BiP [27]. As in
VPAC1 the ﬁrst Asn is located at position 58, we would expect that
VPAC1 will preferentially interact with calnexin. The observation that
wt VPAC1 binds both calnexin and BiP further supports our hypothesis
that wt VPAC1 is inefﬁciently processed by the CHO cells.
Receptor homodimerization, heterodimerization or oligomerization
is nowwell established and considered as an important determinant of
GPCR activity. Consequences of oligomerization vary from a receptor to
another and may lead to modiﬁcation of physiological and pharmaco-
logical ligand recognition, of signalling properties or of desensitization
and internalization proﬁles. As mentioned before some GPCRs are
dimerized in the ER, an apparent requisite for correct delivery to the cell
surface [24,28]. Intracellular association of GPCR could lead to either cell
surface targeting of misrouted receptor as seen for α1D-adrenergic
receptor [29,30] or to intracellular retention of the complex as seen for
V2 vasopressin, D2 and D3-dopamine and α2B-adrenergic receptors
[20,31]. Here, we did not found any clear evidences that such a
mechanism occurs for VPAC1 receptors. Indeed, in cells co-expressing
wt and ng-VPAC1, wt receptors were still mainly expressed at the cell
surface and we never detected cell surface labelling of misrouted ng-
VPAC1. These results suggest that in the stable cell clone studied both
homo- and heterodimers coexist. The trafﬁcking proﬁle of wt and ng-
VPAC1 homodimers remains unchanged while it is likely that hetero-
dimers fail to reach the cell surface. Unfortunately it is difﬁcult to
compare reliably relative expression levels in stable transfection system
and transient transfection often leads to protein aggregation and
misinterpretation of results.
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also showed that misrouted ng-VPAC1 could be partially rescued by
lowering culture temperature. As increase in receptor numbers alone
cannot explain this phenomenon (proteasome inhibition increased
similarly receptors expression levels but did not target ng-VPAC1 to
cell surface), it is likely that lowering culture temperature allows
misfolded VPAC1 to escape the complex co- and post-translational
quality control mechanisms regulating expression of VPAC1 or stabi-
lizes receptor conformation. The non-glycosylated receptors that
reach the membrane were functional.
Finally, besides protein translation, another vesicular way that
delivers receptor at the cell surface is a consequence of receptor
internalization in response to agonist exposure [32]. Like most GPCRs,
VPAC1 receptors are rapidly phosphorylated (mainly by GRK) and
internalized following agonist exposure but do not recycle back to the
cell surface after agonist removal [14,33]. However, wewere unable to
establish a direct correlation between the VPAC1 phosphorylation
level and internalization [14]. Agonist-stimulated ubiquitination of
GPCRs can also modulate their internalization and post-endocytic
trafﬁcking [4], but study of non-ubiquitinatable VPAC1 revealed that
such amechanismdid not account for cell surface expression of VPAC1.
In conclusion, we demonstrated that only a fraction of newly
synthesized VPAC1 attains properly conformation that allows their
cell surface targeting. Misfolded or immature VPAC1 are taken inFig. 9. Effect of lowering culture temperature to 30 °C on expression of ng-VPAC1.
A) CHO cells stably transfected with ng-VPAC1 were cultured for 72 h at 37 °C (left
panel) or 30 °C (right panel) then labelled usingmousemonoclonal anti-MYC. Receptors
were visualized using FITC-conjugated goat anti-mouse IgG using axiovert microscope
equipped with apotome. Scale bar is 10 μM and represents scale for all panels. B) Total
cell lysate of untransfected CHO cells (lane 1) or cells stably transfected with ng-VPAC1
and cultured for 72 h at 37 °C (lane 2) or 30 °C (lane 3) were resolved on 9% acrylamide-
SDS gels, transferred to nitrocellulose membrane and blotted with monoclonal anti-
MYC (upper panel). The membrane was then stripped and re-probed using monoclonal
anti-GAPDH (bottom panel).
Fig. 10. Effect of tunicamycin treatment on expression of VPAC1. A) CHO cells stably
transfected with wt VPAC1 were treated (right panel) or not (left panel) for 24 h with
2 μg/ml tunicamycin then labelled using mouse monoclonal anti-VPAC1. Receptors were
visualized using FITC-conjugated goat anti-mouse IgG using axiovert microscope
equipped with apotome. Scale bar is 10 μM and represents scale for all panels. B) Total
cell lysate of untransfected CHO cells (lane 1) or cells stably transfected with wt VPAC1
and treated (lane 3) or not (lane 2) for 24 h with 2 μg/ml tunicamycin were resolved on
9% acrylamide-SDS gels, transferred to nitrocellulose membrane and blotted with
polyclonal anti-VPAC1 (upper panel). The membrane was then stripped and re-probed
using monoclonal anti-GAPDH (bottom panel).charge by complex co- and post-translational quality control that
involves: 1) calnexin-dependent folding strictly through a glycan-
dependent mechanism, 2) BiP-dependant folding, 3) translocation to
the cytoplasm and proteasome-dependent degradation of improper
proteins, and 4) post-ER quality control check points. This study
provides the basis for futureworks and the consequences, if any, of the
quality control of family B GPCRmembers and their mutual inﬂuences
in pathological conditions modifying protein translation such as ER
stress induced by glucolipotoxity observed in type 2 diabetes.
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